Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-27
1998-04-28
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514281, A61K 31435
Patent
active
057444765
ABSTRACT:
This invention provides for a method of raising extracellular brain acetylcholine levels to improve cognition by the administration to a warm-blooded animal of a pharmaceutical composition comprising an effective amount of a dopamine D.sub.1 agonist.
REFERENCES:
patent: 4785014 (1988-11-01), Goldman-Rakie et al.
patent: 4847300 (1989-07-01), Arnsten et al.
patent: 5047536 (1991-09-01), Nichols
patent: 5300642 (1994-04-01), Earl et al.
patent: 5420134 (1995-05-01), Nichols
Arnsten et al., Nov. 7-12, 1993, "Dopamine D.sub.1 Agonists Improve Spatial Working Memory Performance In Monkeys," Society For Neuroscience Abstracts, vol. 19, Part 1, p. 367, No. 1 153.1.
Arnsten et al., Oct. 1994, "Dopamine D.sub.1 receptor mechanisms in the cognitive performance of young adult and aged monkeys," Psychopharmacology, 116(2):143-151.
Schneider et al., Brain Research, vol. 663, pp. 140-144, 1994.
Acquas, E. et al., 1994, "The Potent and Selective Dopamine D.sub.1 Receptor Agonist A-77636 Increases Cortical and Hippocampal Acetylcholine Release in the Rat", Eur. J. Pharmacol. 260:85-87.
Archer, T. et al., 1988, "Neonatal 6-Hydroxydopamine-Induced Dopamine Depletions: Motor Activity and Performance in Maze Learning", Pharmacol. Biochem. Behav. 31:357-364.
Arendt, T. et al, 1985, "Nueronal Loss in Different Parts of the Nucleus Basalis is Related to Neuritis Plaque formation in Cortical Target Areas in Alzheimer's Disease", Neurosci., 14:1-14.
Bartus, R. et al., 1985, "Selective Memory Loss Following Nucleus Basalis Lesions: Long Term Behavioral Recovery Despite Persistent Cholinergic Deficiencies", Pharmacol. Biochem. Behav. 23:125-135.
Bertorelli, R. and Consolo, S., 1990, "D.sub.1 and D.sub.2 Dopaminergic Regulation of Acetylcholine Release from Striata of Freely Moving Rats", J. Neurochem. 54:2145-2148.
Bianchine, J., 1985, "Drugs for Parkinson's Disease, Spasticity. and Acute Muscle Spams", In: The Pharmacological Basis of Therapeutics, ed.: Gilman et al., pp. 473-490, Macmillan Publishing Co., New York.
Brewster, W. et al., 1990, Highly Potent Selective Dopamine D.sub.1 Full Agonist" J. Med. Chem. 33:1756-1764.
Brown, R. and Marsden, C., 1984, "How Common is Dementia in Parkinson's Disease?", Lancet ii:1262-1265.
Brozoski, T. et al., 1979, "Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey", Science 205:929-932.
Caine, D., 1978, "Parkinsonism--Clinical and Neuropharmacological Aspects", Postgrad. Med. 64:82-88.
Castellano, C. et al., 1991, "Post-Training Dopamine Receptor Agonists and Antagonists Affect Memory Storage in Mice Irrespective of Their Selectivity for D1 or D2 Receptors", Behav. Neural. Biol. 56:283-291.
Colombo, P. et al., 1989, "Allocentric Spatial and Tactile Memory Impairments in Rats With Dorsal Caudate Lesions Are Affected by Preoperative Behavioral Training", Behav. Neurosci. 103:1242-1250.
Creese, I., 1987, "Biochemical Properties of CNS Dopamine Receptors", In: Psychopharmacology: The Third Generation of Progress, ed.:H. Meltzer, pp. 257-264, Raven Press, New York.
Cummings, J., 1988, "The Dementias of Parkinson's Disease: Prevalence, Characteristics, Neurobiology, and Comparison with Dementia of the Alzheimer Type", Eur. Neurol. 28 (suppl. 1):15-23.
Curtis, L. et al., 1984, "Effect of L-Dopa on Course of Parkinson's Disease", Lancet ii:211-212.
Damsma, G. et al., 1990, "Dopaminergic Regulation of Striatal Cholinergic Interneurons: An In Vivo Microdialysis Study", Arch. Pharmacol. 342:523-527.
Damsma, G. et al., 1990, "Dopamine D.sub.1 Receptor Stimulation Increases Striatal Acetylcholine Release in the Rat", Eur. J. Pharmacol. 186:335-338.
Darney, K. et al., 1991, "Behavioral Effects in the Rat of Dihydrexidine, a High-Potency, Full-Efficacy D.sub.1 Dopamine Receptor Agonist", Neuropsychopharmacol. 5:187-195.
Davidson, M. et al., 1991, "Cholinergic Strategies in the Treatment of Alzheimer's Disease", Acta Psychiatr. Scand. (suppl. 366):47-51.
Day, J. and Fibiger, H., 1993, "Dopaminergic Regulation of Cortical Acetylcholine Release: Effects of Dopamine Receptor Agonists", Neurosci. 54:643-648.
Dubois, B. et al., 1985, "Profound Disturbances of Spontaneous and Learned Behaviors Following Lesions of the Nucleus Basalis Magnocellularis in the Rat", Brain Res. 338:249-258.
Dubois, B. et al., 1992, "Deterioration of Dopaminergic Pathways and Alterations in Cognition and Motor Functions", J. Neurol. 239 (suppl. 1):S9-S12.
Dunnett, S., 1985, "Comparative Effects of Cholinergic Drugs and Lesions of Nucleus Basalis or Fimbria-Fornix Delayed Matching in Rats", Psychopharmacol. 87:357-363.
Girotti, F. et al., 1988, "Dementia and Cognitive Impairment in Parkinson's Disease", J. Neurol. Neurosurg. Psych. 51:1498-1502.
Goetz, C., 1990, "Dopaminergic Agonists in the Treatment of Parkinson's Disease", Neurology 40 (suppl. 3):50-57.
Imperato, A. et al., 1993, "Stimulation of Both Dopamine D.sub.1 and D.sub.2 Receptors Facilitates In Vivo Acetylcholine Release in the Hippocampus", Brain Res. 618:341-345.
Iorio, L. et al., 1983, "SCH 23390, a Potential Benzazepine Antipsychotic with Unique Interactions on Dopaminergic Systems", J. Pharmacol. Exp. Ther. 226:462-468.
Kirkby, R. and Polgar, S., 1974, "Active Avoidance in the Laboratory Rat Following Lesions of the Dorsal or Ventral Caudate Nucleus", Physiol. Psychol. 2:301-306.
Kish, S. et al., 1988, "Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease", New Eng. J. Med. 318:876-880.
Koller, W., 1989, "Diagnosis and Treatment of Parkinson's Disease", Mod. Med. 57:114-129.
Lees, A., 1985. "Parkinson's Disease and Dementia", Lancet i:43-44.
Levin, E. and Rose, J., 1991, "Interactive Effects of D.sub.1 and D.sub.2 Agonists with Scopolamine on Radial-Arm Maze Performance", Pharmacol. Biochem. Behav. 38:243-246.
Lovenberg, T. et al., 1989, "Dihydrexidine, a Novel Selective High Potency Full Dopamine D-1 Receptor Agonist", Eur. J. Pharmacol. 166:111-113.
Major, R. and White, N., 1978, "Memory Facilitation by Self-Stimulation Reinforcement Mediated by the Nigro-Neostriatal Bundle", Physiol. Behav. 20:723-733.
McGaugh, J., 1966, "Time-Dependent Processes in Memory Storage", Science 153:1351-1358.
McGurk, S. et al., 1992, "Dopaminergic Drugs Reverse the Impairment of Radial Arm Maze Performance Caused by Lesions Involving the Cholinergic Medial Pathway", Neurosci. 50:129-135.
Mottola, D. et al., 1992, "Dihydrexidine, a Novel Full Efficacy D.sub.1 Dopamine Recpetor Agonist", J. Pharmacol. Exp. Ther. 262:383-393.
Mountjoy, C. et al., 1984, "Correlation of Cortical Cholinergic and GABA Deficits with Quantitative Neuropathological Findings in Senile Dementia", Brain 107:507-518.
Murray, C. and Fibiger, H., 1985, "Learning and Memory Deficits After Lesions of the Nucleus Basalis Magnocellularis: Reversal by Physostigmine", Neurosci. 14:1025-1032.
Neill, D. et al., 1974, "Impairment of Avoidance Performance bby Intrastriatal Administration of 6-Hydroxydopamine", Pharmacol. Biochem. Behav. 2:97-103.
Olton, D. and Wenk, G., 1987, "Dementia: Animal Models of the Cognitive Impairments Produced by Degeneration of the Basal Forebrain Cholinergic System", In: Psychopharmacology: The Third Generation of Progress, ed.: H. Meltzer, pp. 941-953, Raven Press, New York.
Packard, M. and White, N. 1989, "Memory Facilitation Produced by Dopamine Agonists: Role of Receptor Subtype and Mnemonic Requirements", Pharmacol. Biochem. Behav. 33:511-518.
Packard, M. et al., 1989, "Differential Effects of Fornix and Caudate Nucleus Lesions on Two Radial Maze Tasks: Evidence for Multiple Memory Systems", J. Neurosci. 9:1465-1472.
Packard, M. and White, N., 1990, "Lesions of the Caudate Nucleus Selectively Impair Reference Memory Acquisition in the Radial Maze", Behav. Neural Biol. 53:39-50.
Packard, M. and White, N., 1991, "Dissociation of Hippocampus and Caudate Nucleus Memory Systems by Posttraining Intracerebral Injection of Dopamine Agonists", Behav. Neurosci. 105:295-306.
Perry, R. et al., 1983, "Cortical Cholinergic Deficit in Mentally Impaired Parkinsonian Patients", Lancet ii:789-790
Locke Kenneth Walter
Steele Thomas David
Interneuron Pharmaceuticals Inc.
Raymond Richard L.
LandOfFree
Dopamine D.sub.1 agonists for the treatment of dementia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dopamine D.sub.1 agonists for the treatment of dementia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine D.sub.1 agonists for the treatment of dementia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1532180